SCHEMBL6203778

SCHEMBL6203778

O=C1NC(=O)C2(CCCN2c2ccc(Oc3ccc(-c4nnc(-c5ccncc5)o4)cc3)nc2)C(=O)N1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 17/20 0.67
KDM4E B2RXH2 3/20 0.36
NPC1 O15118 2/20 0.36
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6204553 0.92 MMP13 (0.68) MMP13
SCHEMBL6202736 0.91 MMP13 (0.63) MMP13KDM4ENPC1ALDH1A1RAB9A
SCHEMBL6204465 0.91 MMP13 (0.67) MMP13KDM4ENPC1RAB9AKMT2A
SCHEMBL6204429 0.91 MMP13 (0.67) MMP13KDM4EALDH1A1
SCHEMBL6203894 0.91 MMP13 (0.82) MMP13
SCHEMBL6205012 0.91 MMP13 (0.67) MMP13
SCHEMBL6204630 0.91 MMP13 (0.64) MMP13KDM4ENPC1ALDH1A1RAB9A
SCHEMBL6201852 0.91 MMP13 (0.64) MMP13KDM4ENPC1ALDH1A1RAB9A
SCHEMBL6204749 0.90 MMP13 (0.79) MMP13
SCHEMBL6202835 0.89 MMP13 (0.64) MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501834-B1 TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-09-07 EP disclosed
US-6916807-B2 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-07-12 US disclosed
EP-1501834-A1 TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-02 EP disclosed
US-20030225056-A1 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2003-12-04 US disclosed
WO-2003091259-A1 TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225056-A1 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP9, TIMP3, MMP8 MMP13 15/4885KDM4E 1998/4885NPC1 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.